Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Juan Carlos Vega;
Boris Fernando Sanchez;
Luz Mery Montero;
Rafael Montaña;
Mercedes Del Pilar Mahecha;
Bladimir Dueñes;
Angela Rocío Baron;
Richard Reithinger;
(2007)
Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Tropical medicine & international health, 12 (12).
pp. 1540-1544.
ISSN 1360-2276
DOI: 10.1111/j.1365-3156.2007.01962.x
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).
| Item Type | Article |
|---|---|
| Keywords | Antiprotozoal Agents, economics, therapeutic use, Colombia, epidemiology, Cost-Benefit Analysis, Disease Outbreaks, economics, Hospital Costs, statistics & numerical data, Humans, Leishmaniasis, drug therapy, economics, epidemiology, Meglumine, economics, therapeutic use, Organometallic Compounds, economics, therapeutic use |
| ISI | 251387300017 |